Clinical Trials Project Management Program

Explore protocol development and study design, defining objectives, eligibility criteria, and ethical, regulatory frameworks and standards, including informed consent and risk assessment, to uphold trial integrity.

Explore the principles of protocol development in clinical research, including objectives, design, eligibility criteria, interventions, and assessments. Emphasize ethics, regulatory requirements, IRB review, and amendments that safeguard safety and data integrity.

Design robust clinical trial protocols by aligning clear objectives with ethical and regulatory standards, ensuring participant safety, informed consent, eligibility, intervention plans, and standardized data collection and analysis.

Explore ethical principles and regulatory frameworks, including FDA and EMA oversight, independent IRBs, informed consent, risk-benefit analysis, and equitable access in study design.

Explore fundamentals of project management in clinical trials, including planning, scheduling, resource management, risk assessment, quality assurance, and stakeholder leadership to meet timelines and improve patient outcomes.

Apply planning, organizing, leading, and controlling to manage clinical trials, defining objectives, timelines, budgets, resources, and risks with ethical integrity and quality-focused scheduling.

Plan and organize clinical trial activities by defining scope, objectives, deliverables, and timelines, while coordinating stakeholders, resources, and milestones to guide Migranex phase iii data collection, regulatory approvals, and submissions.

Explore how clear communication, proactive risk management, and adaptive leadership enhance coordination, stakeholder engagement, and effective project management in clinical trials.

Explore randomized controlled trials as the gold standard for evaluating medical interventions, covering design, randomization, blinding, informed consent, and ethics.

Randomized controlled trials evaluate interventions by random assignment to intervention and control groups, using blinding to minimize bias and encompass parallel-group, crossover, factorial, and cluster-randomized RCT designs.

Explore how randomization and well-chosen control groups, blinding, and diverse RCT designs uphold validity in clinical trials, while protecting autonomy, beneficence, non-maleficence, and informed consent under IRB oversight.

Master the implementation and management of randomized controlled trials by aligning study protocols, recruitment, randomization, informed consent, safety monitoring, data integrity, and ethical oversight.

Develop expertise in data safety monitoring to protect participant welfare and trial integrity. Learn the roles of data and safety monitoring boards, monitoring plans, stopping rules, and regulatory guidelines.

Data safety monitoring upholds beneficence, respect for persons, and justice in clinical trials, protecting participants and ensuring credible, reliable findings through independent DSMBs or DMCs.

Learn how data and safety monitoring boards (DSMBs) safeguard participant safety and trial integrity through independent oversight, interim analyses, and stopping rules, illustrated by SPRINT, RE-LY, and ASPREE.

Develop and implement data safety monitoring plans to protect participant welfare and trial integrity by defining stopping rules, data collection procedures, and the roles of independent monitoring committees.

Explore pharmacovigilance principles, identify and report adverse drug reactions, and understand systems that safeguard patient safety and public health. Learn to monitor, assess, and communicate risk across the drug lifecycle.

Explore pharmacovigilance principles, including detecting and evaluating adverse events, signal detection, risk minimization, and collaboration among stakeholders to safeguard patient safety across clinical trials and post-marketing contexts.

Identify, assess, and report adverse drug reactions to safeguard patient safety and advance pharmacovigilance through timely recognition, causality assessment, and compliant reporting.

Pharmacovigilance systems monitor drug safety across the lifecycle by collecting adverse event reports, detecting signals with data mining, and guiding risk management to protect patient health.

Explore the classification, severity assessment, causality, and reporting of adverse events in clinical trials. Review documentation and ensure regulatory compliance to protect participant safety and data integrity.

Classify adverse events as serious or non-serious, assess severity with CTCAE, determine causality with tools like Naranjo and WHO-UMC, and ensure timely regulatory reporting and documentation.

Learn how to identify, assess, and document adverse events in clinical trials using CTCAE grading, Naranjo scale, and WHO-UMC criteria, aligned with FDA and EMA regulatory guidelines.

Master regulatory requirements for adverse event reporting, including expedited reporting, seriousness and unexpectedness criteria, and periodic safety update reports, while ensuring accurate documentation and robust quality assurance.

Navigate site selection and qualification for clinical trials, conduct feasibility assessments and pre-study visits, evaluate infrastructure, expertise, patient demographics, and regulatory requirements to ensure site readiness and trial success.

Explore comprehensive criteria for selecting clinical trial sites, from infrastructure and regulatory compliance to investigator expertise and patient recruitment, illustrated by cancer center and stroke center case studies.

Plan and conduct pre-study visits to assess site facilities, staff qualifications, regulatory compliance, data management, and logistics to select suitable sites and ensure trial readiness.

Assess and qualify clinical trial sites by evaluating infrastructure, expertise, patient population, and regulatory compliance, using site visits and documentation to ensure data quality and patient safety.